Our findings revealed that MRM2, NSUN4, TFB1M, and TRMT2B were correlated significantly with most immunomodulators in glioma, whereas MRM1 and RPUSD4 were correlated negatively (Figure 2A). This evidence concerns the gene TFB1M and central nervous system cancer.